Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
A-Z
> Cardiac-related Solutions & Services Explore our cardiac organoid products and services and how we can assist with cardiac modeling, organoid identification, and drug screening / testing. We now offer ready-to-use cardiac organoids, cardiac organoid differentiation services, and testing services that includes cell activity assays and electrophysiological studies.
Cardiac models play a pivotal role in studying heart-related conditions and assessing drug toxicity under cardiac-related conditions. Since cardiotoxicity testing is a prerequisite before clinical studies, using a relevant cardiac model is essential. We offer a wide range of products and services that encompass cardiac disease modeling, cardiac organoid identification, and drug screening services using cardiac organoid disease models.
Cardiac Organoids
Cardiac organoids are a miniaturized, in vitro version of the heart that is derived from either induced pluripotent stem cells (iPSC) or tissue fragments. These organoids are designed to have a similar cellular composition and architecture as the heart, while exhibiting similar mechanophysiological and electrophysiological properties. As such, cardiac organoids are a critical tool for researchers developing treatments for cardiovascular diseases, driving different applications such as:
Cardiotoxicity
Screening
Cardiotoxicity
Screening
Cardiac organoids derived from human cells mimic native heart tissue and functional properties resulting in a scalable, high-throughput drug screening assay.
Cardiac Disease
Modeling
Cardiac Disease
Modeling
Cardiac organoids derived from human cells mimic native heart tissue and functional properties resulting in a scalable, high-throughput drug screening assay.
Personalized Drug
Screening
Personalized Drug
Screening
Cardiac organoids derived from human cells mimic native heart tissue and functional properties resulting in a scalable, high-throughput drug screening assay.
Ready-to-use cardiac organoids are differentiated using our cardiac organoid kit (Ca. No. RIPO-HWM002K) and are designed to assist with drug efficacy and safety evaluations, as well as pharmacological research.
Cardiac organoids differentiated using the Human iPSC-Derived Cardiac Organoid Differentiation Kit (Ca. No. RIPO-HWM002K) show regular beating from day 7-13 of differentiation and calcium imaging.
| Cat. No. | Description |
| CIPO-HWL002K | Ready-to-use Human iPSC-derived Cardiac Organoids |
| RIPO-HWM002K | Human iPSC-derived Cardiac Organoid Differentiation Kit |
| RIPO-HWM004 | Human iPSC-derived Cardiac Organoid Maintenance Kit |
| RIPO-HWM005 | Cardiac Organoid Cryopreservation Kit |
Cardiac Cells
iPSC-derived cardiomyocytes validated with cardiac troponin (cTnT) can be provided for your studies into various cardiac-related diseases. This cell line is designed for cardiotoxicity screening and evaluation of electrical signal propagation through cardiomyocytes.
Interested? Leave a message!
Cardiac Services
We also provide various study services related to organoids differentiation, identification, and safety evaluations. This encompasses multiple molecular experimental platforms such as western blot, immunofluorescence, and qPCR. Our relioable electrophysiological platform using microelectrode arrays and patch clamps enables us to evaluate cardiac viability through the visualization of electric signal propogation derived from ion channel fucntion and ion uptake.
We offer differentiation services to develop cardiac organoids from iPSCs or human tissue. Organoids are validated by the expression of heart-related protein markers to ensure differentiation and maturity.
We can help measure the inhibitory effect of ion-channel blocking drugs (such as hERG potassium channels) on cardiomyocytes to better predict drug cardiotoxicity.
We can help construct a heart-failure model using our cardiac organoids derived from iPSCs for high-thoroughput drug candidate testing to screen for the ideal drug candidates.
Cardiac Case Studies
Using our MEA platform, cardiac organoids exposed to Drug C (potassium channel inhibitor) were measured to evaluate its effect on its electric signal propagation. Ordinarily, the organoid itself is capable of self-polarization and de-polarization, manifesting as a rhythmic beating that is observable through a microscope. Re- and de-polarization was evaluated by MEA to identify any abnormal electrophysiological indicators under the influence of drug C.
References
1. Blinova et al., 2017, Toxicol Sci (about CiPA iPSC-CM benchmark| Performance)
2. Hofbauer, P., Jahnel, S.M., Papai, N., et al. Cardioids reveals self-organizing principles of human cardiogenesis. Cell (2021), DOI: https://doi.org/10.1016/j.cell.2021.04.034
This web search service is supported by Google Inc.
